Correlation between Serum Prostate Specific Antigen levels with Incidence of Bone Metastases in Newly Diagnosed Prostate Cancer Patients in Indian Population

Title: Correlation between Serum Prostate Specific Antigen levels with Incidence of Bone Metastases in Newly Diagnosed Prostate Cancer Patients in Indian Population

Authors: Amit Sharma, Sumit Agarwal, MS Chauhan, AK Yadav, Anurag Jain, IP Dubey, Rajeev Kumar, Braj Kishore, MG Vishnoi, Dharmesh Paliwal, Arun Ravi John, Neeraj

DOI: https://dx.doi.org/10.18535/jmscr/v5i3.06

Abstract

Introduction: Prostate cancer is second most frequently diagnosed cancer of men and bone is the commonest site of metastasis in them. There is lack of consensus for the selection criteria for bone scan in low risk patients. Western guidelines do not recommend use of bone scan in asymptomatic patients and in low PSA values. We try to correlate the PSA value with bone metastases through bone scan in Indian population.

Material and Methods: 89 males of histologically proven carcinoma prostate over the period of 15 months, from March 2014 to May 2015 were included in the study. The patients were stratified into 3 groups according to their PSA level: the first group of patients had PSA level ranging from 0 - 10 ng/ml (n = 32), the second group had PSA level ranging from 10.1 - 20 ng/ml (n= 9), the third group had PSA levels > 20 ng/ml (n = 48).

Results: The incidence of osseous metastases proven by bone scintigraphy was found to be 25% (8 out of 32) for PSA level 0 - 10 ng/ml, to 22.2 % (2 out of 9) for PSA level 10.1-20 and 68.7% (33 out of 48) for PSA level > 20 ng/ml (P < 0.001). The incidence of bone metastases < 20ng/ml is 21.73 % (10/46) (table-3). All patients (n=17) with PSA value>100 ng/ml were having bone metastases.

Conclusion: The correlation between PSA value and both presence and metastases confirms the usefulness of bone scan scintigraphy in prostate cancer staging. Bone scan should be part of initial evaluation in all patients irrespective of serum PSA value as even patients with PSA values< 20 ng/ml are presenting with bone metastases.There should not be any minimal threshold limit of PSA for referring patients to bone scan.

References

1. Jemal A, Center MM, DeSantis C, Ward EM (2010). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev, 19, 1893-907. Center MM, Jemal A, Lortet-Tieulent J, et al (2012). International variation in prostate cancer incidence and mortality rates.Eur Urol, 61, 1079-92.

2. Matsuda T, Saika K (2009). Comparison of time trends in prostate cancer incidence (1973-2002) in Asia, from cancer incidence in five continents, Vols IV-IX. Jpn J Clin Oncol.

3. Bubendorf L, Schöpfer A, Wagner U, et al (2000). Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum pathol, 31, 578-83. 39, 468-9.

4. Nguyen DX, Bos PD, Massagué J (2009). Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer, 9, 274-84

5. Sadik M, Suurkula M et al (2008). Quality of planar whole-body bone scan interpretations-a nationwide survey. Eur J Nucl Med Mol Imaging, 35, 1464-72

6. Briganti A, Passoni N, Ferrari M, et al (2010). When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol,57, 551-8.

7. Axel Heidenreich a,*, et al: EAU Guidelines on Prostate Cancer

8. Zaman MU, Fatima N, Sajjad Z (2011). Metastasis on bone scan with low prostate specific antigen (=20 ng/ml) and Gleason’s score (<8) in newly diagnosed Pakistani males with prostate cancer: should we follow Western guidelines? Asian Pac J Cancer Prev, 12, 1529-32.

9. Ito K, Kubota Y, Suzuki K, et al (2000). Correlation of prostate specific antigen before prostate cancer detection and clinicopathologic features: evaluation of mass screening populations. Urol, 55,705-9

10. Yang G, Zuo S, Ma C, et al (2009). The diagnostic correlations of bone scintigr-aphy, pathological grade and PSA for metastatic prostate cancers. The Chinese-German J Clinical Oncol, 8, 702-4.

11. I Putu Gde Sanjaya et al (2013) Incidence of Bone Metastases in Prostate Cancer Patients with Low Gleason Score and PSA Levels, Asian Pacific Journal of Cancer Prevention, Vol 14, 2013, 14 (9), 4973-4976

12. Pal RP, Thiruudaian T, Khan MA (2008). When is a bone scan study appropriate in asymptomatic men diagnosed with prostate cancer? Asian J Androl, 10, 890-5.

13. Salonia A, Gallina A, Cior T, et al (2006). Bone metastasis are infrequent in patients with newly diagnosed prostate cancer: Analysis of their clinical and pathological features.Urology, 68, 362-6

14. Chan, Jou et al, 2004. The relative impact and future burden of prostate cancer in the united states, November 2004 Volume 172, Issue 5, Supplement, Pages S13–S17

15. Ataus S, Citçi A, Alici B, Onder AU, Sönmezoğlu K, Erözenci A, et al. The value of serum prostate specific antigen and other parameters in detecting bone metastases in prostate cancer. Int Urol Nephrol. 1999; 31: 481–489.

16. Rydh A, Tomic R, Tavelin B, Hietala SO, Damber JE. Predictive value of prostate-specific antigen, tumour stage and tumour grade for the outcome of bone scintigraphy in patients with newly diagnosed prostate cancer. Scand J Urol Nephrol. 1999; 33: 89–93.

17. Bantis A, Grammaticos P. Prostatic specific antigen and bone scan in the diagnosis and follow-up of prostate cancer. Can diagnostic significance of PSA be increased? Hell J Nucl Med. 2012; 15(3): 241–246.

18. Lai MH, Luk WH, Chan JC (2011). Predicting bone scan findings using sPSA in patients newly diagnosed of prostate cancer: Feasibility in Asian population. Urol Oncol, 29, 275-9.

19. Koramadai Karuppusamy Kamaleshwaran et al (2012) Predictive value of serum prostate specific antigen in detecting bone metastasis in prostate cancer patients using bone scintigraphy. Indian J Nucl Med. 2012 Apr-Jun; 27(2): 81–84

20. Kanthilatha Pai et al, Diagnostic Correlation between Serum PSA, Gleason Score and Bone Scan Results in Prostatic Cancer Patients with Bone Metastasis, BBB[3][01][2015]001-007

21. Oommen R Correlation of serum prostate specific antigen levels and bone scintigraphy in carcinoma prostate. Br J Radiol. 1994 May;67(797):469-71.

22. Data were provided by the Office for National Statistics on request, July 2013. Similar data can be found here:http://www.ons.gov.uk/ons/rel/vsob1/cancer-statistics-registrations--england--series-mb1-/index.html(link is external).

23. Data were provided by ISD Scotland on request, May 2013. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp(link is external).

24. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit on request, June 2013. Similar data can be found here:http://www.wales.nhs.uk/sites3/page.cfm?orgid=242&pid=59080(link is external).

25. Data were provided by the Northern Ireland Cancer Registry on request, June 2013. Similar data can be found here:http://www.qub.ac.uk/research-centres/nicr/CancerData/OnlineStatistics/(link is external).

Abstract

References

Corresponding Author

Call For Paper Volume 12 Issue 10 November 2024

JMSCR Menu

Impact Factor SJIF 2024: 7.892

Crossref - DOI

Editorial Policy

Frequency of Publication

Submission of Articles

Search

Abstract

Call For Paper Volume 12 Issue 10 November 2024

JMSCR Menu

Impact Factor SJIF 2024: 7.892

Crossref - DOI

Editorial Policy

Frequency of Publication

Submission of Articles